View article

Tuberculosis remains a formidable global health challenge, causing substantial morbidity and mortality due to the limited protection in the lungs provided by the current BCG vaccine. 1 The urgent need for an effective tuberculosis vaccine has prompted innovative approaches to accelerate vaccine development. One such approach is the use of controlled human infection models, which offer a unique opportunity to evaluate candidate tuberculosis vaccines in a cost-effective manner. 2 Although the concept is not new, 3 developing such models for tuberculosis research presents unique challenges because the use of Mycobacterium tuberculosis, the causative agent of tuberculosis, as a challenge agent is not ethical. As a safer alternative, a skin challenge model—using the live attenuated Mycobacterium bovis BCG vaccine as a surrogate for M tuberculosis—has been studied with commendable results. 4, 5 However …